Reviva Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) saw unusually large options trading on Tuesday. Stock traders acquired 13,196 call options on the stock. This represents an increase of 374% compared to the average volume of 2,782 call options.

Reviva Pharmaceuticals Stock Down 3.0 %

RVPH stock opened at $1.94 on Thursday. The firm has a market cap of $64.88 million, a price-to-earnings ratio of -1.75 and a beta of -0.12. The company’s fifty day simple moving average is $1.68 and its 200 day simple moving average is $1.33. Reviva Pharmaceuticals has a 12-month low of $0.60 and a 12-month high of $4.83.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Reviva Pharmaceuticals stock. Drive Wealth Management LLC bought a new position in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 20,000 shares of the company’s stock, valued at approximately $36,000. Drive Wealth Management LLC owned approximately 0.06% of Reviva Pharmaceuticals as of its most recent SEC filing. 63.18% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on RVPH. Roth Mkm began coverage on shares of Reviva Pharmaceuticals in a report on Friday, January 10th. They issued a “buy” rating and a $7.00 price objective for the company. Roth Capital upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 10th. Maxim Group upgraded Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a report on Friday, January 10th. D. Boral Capital reaffirmed a “buy” rating and set a $15.00 target price on shares of Reviva Pharmaceuticals in a report on Tuesday. Finally, HC Wainwright decreased their price target on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $11.40.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.